Back to results
US 12,644,111 B2Granted
CRISPR enzymes and systems
AssigneesThe Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
InventorsFeng Zhang, Ian Slaymaker, Soumya Kannan, Jonathan Gootenberg, Omar Abudayyeh
Life of this patent
Estimating the term…
Abstract
The present disclosure provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides mutated Cas13 proteins and their use in modifying target sequences as well as mutated Cas13 nucleic acid sequences and vectors encoding mutated Cas13 proteins and vector systems or CRISPR-Cas13 systems.
Claims20
A non-naturally occurring or engineered composition comprising:
- (a) a Type VI Cas protein comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO. 274;
- (b) a heterologous guide sequence capable of forming a complex with the Type VI Cas protein and directing the complex to bind to a target sequence;
- and
- (c) one or more functional domains wherein at least one of the one or more functional domains is an adenosine deaminase or a cytidine deaminase, and
- wherein the Type VI Cas protein is directly linked with the one or more functional domains.
2 more elements
A non-naturally occurring or engineered composition comprising:
- (a) a Type VI Cas protein comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO. 274;
- (b) a nucleotide deaminase fused or linked to the Cas protein and
- (c) a guide sequence capable of forming a complex with the Type VI Cas protein and directing the complex to bind to a target sequence,
- wherein the Type VI Cas protein is catalytically inactive and comprises an N-terminal truncation, a C-terminal truncation, or both relative to the amino acid sequence of SEQ ID NO. 274.
1 more element
Dependencies are inferred from the claim text.